Site-specifically biotinylated VEGF 121 for near-infrared fluorescence imaging of tumor angiogenesis

Molecular Pharmaceutics

Volumn 6, Issue 1, 2009, Pages 285-294

  Wang, Hui ^a   Chen, Kai ^a   Niu, Gang ^a   Chen, Xiaoyuan ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Angiogenesis; Avi tag; Near Infrared fluorescence imaging; Site specific biotinylation; Vascular endothelial growth factor (VEGF)

Indexed keywords

BIOTIN; LIGASE; PROTEIN BIRA; STREPTAVIDIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BIOTINYLATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLUORESCENCE IMAGING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANIMAL; CELL LINE; CHEMISTRY; ENZYME SPECIFICITY; FLUORESCENCE MICROSCOPY; HUMAN; INFRARED SPECTROPHOTOMETRY; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); SWINE; VASCULARIZATION;

ANIMALS; BIOTIN; CELL LINE; HUMANS; MICROSCOPY, FLUORESCENCE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SPECTROPHOTOMETRY, INFRARED; SUBSTRATE SPECIFICITY; SWINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 62649089820     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp800185h     Document Type: Article

References (31)

1. Ferrara, N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer 2002, 2, 795-803.
2. Roodhart, J. M.; Langenberg, M. H.; Witteveen, E.; Voest, E. E. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr. Clin. Pharmacol. 2008, 3, 132-43.
3. Underiner, T. L.; Ruggeri, B.; Gingrich, D. E. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Curr. Med. Chem. 2004, 11, 731-45.
4. Sun, J.; Wang, D. A.; Jain, R. K.; Carie, A.; Paquette, S.; Ennis, E.; Blaskovich, M. A.; Baldini, L.; Coppola, D.; Hamilton, A. D.; Sebti, S. M. Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. Oncogene 2005, 24, 4701-9.
5. Watanabe, H.; Mamelak, A. J.; Wang, B.; Howell, B. G.; Freed, I.; Esche, C.; Nakayama, M.; Nagasaki, G.; Hicklin, D. J.; Kerbel, R. S.; Sauder, D. N. Anti-vascular endothelial growth factor receptor-2 (Flk-1/KDR) antibody suppresses contact hypersensitivity. Exp. Dermatol. 2004, 13, 671-81.
6. Prewett, M.; Huber, J.; Li, Y.; Santiago, A.; O'Connor, W.; King, K.; Overholser, J.; Hooper, A.; Pytowski, B.; Witte, L.; Bohlen, P.; Hicklin, D. J. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angio- genesis and growth of several mouse and human tumors. Cancer Res. 1999, 59, 5209-18.
7. Wedge, S. R.; Ogilvie, D. J.; Dukes, M.; Kendrew, J.; Curwen, J. O.; Hennequin, L. F.; Thomas, A. P.; Stokes, E. S.; Curry, B.; Richmond, G. H.; Wadsworth, P. F. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res. 2000, 60, 970-5.
8. Wood, J. M.; Bold, G.; Buchdunger, E.; Cozens, R.; Ferrari, S.; Frei, J.; Hofmann, F.; Mestan, J.; Mett, H.; O'Reilly, T.; Persohn, E.; Rosel, J.; Schnell, C.; Stover, D.; Theuer, A.; Towbin, H.; Wenger, F.; Woods-Cook, K.; Menrad, A.; Siemeister, G.; Schirner, M.; Thierauch, K. H.; Schneider, M. R.; Drevs, J.; Martiny-Baron, G.; Totzke, F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor- induced responses and tumor growth after oral administration. Cancer Res. 2000, 60, 2178-89.
9. Nagengast, W. B.; de Vries, E. G.; Hospers, G. A.; Mulder, N. H.; de Jong, J. R.; Hollema, H.; Brouwers, A. H.; van Dongen, G. A.; Perk, L. R.; Lub-de Hooge, M. N. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J. Nucl. Med. 2007, 48, 1313-9.
10. Wang, H.; Cai, W.; Chen, K.; Li, Z. B.; Kashefi, A.; He, L.; Chen, X. A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur. J. Nucl. Med. Mol. Imaging 2007, 34, 2001-10.
11. Collingridge, D. R.; Carroll, V. A.; Glaser, M.; Aboagye, E. O.; Osman, S.; Hutchinson, O. C.; Barthel, H.; Luthra, S. K.; Brady, F.; Bicknell, R.; Price, P.; Harris, A. L. The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res. 2002, 62, 5912-9.
12. Li, S.; Peck-Radosavljevic, M.; Koller, E.; Koller, F.; Kaserer, K.; Kreil, A.; Kapiotis, S.; Hamwi, A.; Weich, H. A.; Valent, P.; Angelberger, P.; Dudczak, R.; Virgolini, I. Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy. Int. J. Cancer 2001, 91, 789-96.
13. Backer, M. V.; Levashova, Z.; Patel, V.; Jehning, B. T.; Claffey, K.; Blankenberg, F. G.; Backer, J. M. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat. Med. 2007, 13, 504-9.
14. Blankenberg, F. G.; Backer, M. V.; Levashova, Z.; Patel, V.; Backer, J. M. In vivo tumor angiogenesis imaging with site- specific labeled (99m)Tc-HYNIC-VEGF. Eur. J. Nucl. Med. Mol. Imaging 2006, 33, 841-8.
15. Korpanty, G.; Carbon, J. G.; Grayburn, P. A.; Fleming, J. B.; Brekken, R. A. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. Clin. Cancer Res. 2007, 13, 323-30.
16. Willmann, J. K.; Paulmurugan, R.; Chen, K.; Gheysens, O.; Rodriguez-Porcel, M.; Lutz, A. M.; Chen, I. Y.; Chen, X.; Gambhir, S. S. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 2008, 246, 508-18.
17. Backer, M. V.; Patel, V.; Jehning, B. T.; Backer, J. M. Self- assembled "dock and lock" system for linking payloads to targeting proteins. Bioconjugate Chem. 2006, 17, 912-9.
18. Lu, E.; Wagner, W. R.; Schellenberger, U.; Abraham, J. A.; Klibanov, A. L.; Woulfe, S. R.; Csikari, M. M.; Fischer, D.; Schreiner, G. F.; Brandenburger, G. H.; Villanueva, F. S. Targeted in vivo labeling of receptors for vascular endothelial growth factor: approach to identification of ischemic tissue. Circulation 2003, 108, 97-103.
19. Li, S.; Peck-Radosavljevic, M.; Kienast, O.; Preitfellner, J.; Hamilton, G.; Kurtaran, A.; Pirich, C.; Angelberger, P.; Dudczak, R. Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy. Ann. Oncol. 2003, 14, 1274-7.
20. Li, S.; Peck-Radosavljevic, M.; Kienast, O.; Preitfellner, J.; Havlik, E.; Schima, W.; Traub-Weidinger, T.; Graf, S.; Beheshti, M.; Schmid, M.; Angelberger, P.; Dudczak, R. Iodine-123-vascular endothelial growth factor-165 (123I-VEGF165). Biodistribution, safety and radiation dosimetry in patients with pancreatic carcinoma. Q. J. Nucl. Med. Mol. Imaging 2004, 48, 198-206.
21. Blankenberg, F. G.; Mandl, S.; Cao, Y. A.; O'Connell-Rodwell, C.; Contag, C.; Mari, C.; Gaynutdinov, T. I.; Vanderheyden, J. L.; Backer, M. V.; Backer, J. M. Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor. J. Nucl. Med. 2004, 45, 1373-80.
22. Choi-Rhee, E.; Schulman, H.; Cronan, J. E. Promiscuous protein biotinylation by Escherichia coli biotin protein ligase. Protein Sci. 2004, 13, 3043-50.
23. Aslakson, C. J.; Miller, F. R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 1992, 52, 1399-405.
24. Willmann, J. K.; Chen, K.; Wang, H.; Paulmurugan, R.; Rollins, M.; Cai, W.; Wang, D. S.; Chen, I. Y.; Gheysens, O.; Rodriguez-Porcel, M.; Chen, X.; Gambhir, S. S. Monitoring of the biological response to murine hindlimb ischemia with 64Cu-labeled vascular endothelial growth factor-121 positron emission tomography. Circulation 2008, 117, 915-22.
25. Mock, D. M.; DuBois, D. B. A sequential, solid-phase assay for biotin in physiologic fluids that correlates with expected biotin status. Anal. Biochem. 1986, 153, 272-8.
26. Levashova, Z.; Backer, M.; Backer, J. M.; Blankenberg, F. G. Direct site-specific labeling of the Cys-tag moiety in scVEGF with technetium 99m. Bioconjugate Chem. 2008, 19, 1049-54.
27. Beckett, D.; Kovaleva, E.; Schatz, P. J. A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation. Protein Sci. 1999, 8, 921-9.
28. Schechter, B.; Silberman, R.; Arnon, R.; Wilchek, M. Tissue distribution of avidin and streptavidin injected to mice. Effect of avidin carbohydrate, streptavidin truncation and exogenous biotin. Eur. J. Biochem. 1990, 189, 327-31.
29. Driegen, S.; Ferreira, R.; van Zon, A.; Strouboulis, J.; Jaegle, M.; Grosveld, F.; Philipsen, S.; Meijer, D. A generic tool for biotinylation of tagged proteins in transgenic mice. Transgenic Res. 2005, 14, 477-82.
30. Rodriguez, P.; Braun, H.; Kolodziej, K. E.; de Boer, E.; Campbell, J.; Bonte, E.; Grosveld, F.; Philipsen, S.; Strouboulis, J. Isolation of transcription factor complexes by in vivo biotinylation tagging and direct binding to streptavidin beads. Methods Mol. Biol. 2006, 338, 305-23.
31. Smith, P. A.; Tripp, B. C.; DiBlasio-Smith, E. A.; Lu, Z.; LaVallie, E. R.; McCoy, J. M. A plasmid expression system for quantitative in vivo biotinylation of thioredoxin fusion proteins in Escherichia coli. Nucleic Acids Res. 1998, 26, 1414-20.